Enlivex stock completes first closing of USD 7.5 million offering
Published on 11/19/2026 at 13:10 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSFunding arrives in stages
- Enlivex completed the initial closing of its registered direct offering on November 17, 2026.
- Investors committed to 10 additional monthly closings, subject to continued Nasdaq or other U.S. exchange listing.
- The company plans to use the proceeds for clinical, regulatory, manufacturing and research activities, as well as potential acquisitions and in-licensing.
Enlivex completed the initial closing of its registered direct offering on November 17, 2026, raising approximately USD 0.5 million in gross proceeds. The company issued 380,232 ordinary shares and warrants to purchase up to the same number of shares, according to the SEC filing published by StockTitan.
The transaction follows Enlivex's November 16 announcement of a registered direct offering with total potential gross proceeds of USD 7.5 million. The company's announcement set the purchase price at USD 1.315 per ordinary share and accompanying warrant, or USD 1.314 per pre-funded warrant and accompanying warrant.
Ten further closings are planned
Investors committed to purchase an additional USD 7.0 million in 10 monthly closings of USD 0.7 million each. The schedule runs from December 1, 2026, through September 1, 2027, subject to continued listing on Nasdaq or another U.S. national exchange. Some closings may be postponed pending shareholder approval to increase authorized share capital or if the registration statement is unavailable.
The ordinary warrants are immediately exercisable at USD 1.578 per share and expire three years after the initial closing. Pre-funded warrants carry an exercise price of USD 0.001 per share and have no expiration date. Enlivex said it intends to use the net proceeds for clinical, regulatory, manufacturing and research and development activities, potential acquisitions and in-licensing, and general corporate purposes.
Enlivex stock traded at 1.11 euros on Lang & Schwarz at 13:05 CET on Thursday, November 19, 2026.
Enlivex Ltd.
- ISIN: IL0011319527
- Ticker: ENLV
- Primary listing: Nasdaq
- Lang & Schwarz price: 1.11 euros on November 19, 2026, at 13:05 CET
Israel's broader market context is covered in the TA-35 market overview.
More news and analyses are available on the Enlivex stock topic page.
